Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Desroziers, Katia ^a   Aballéa, Samuel ^a   Maman, Khaled ^a   Nazir, Jameel ^b   Odeyemi, Isaac ^b   Hakimi, Zalmai ^c  

^a CREATIV CEUTICAL   (France)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^c Astellas Pharma Global Development   (Netherlands)

Author keywords

EQ 5D; Health related quality of life; OAB 5D; Overactive bladder; Quality adjusted life years; Utility assessment

Indexed keywords

MIRABEGRON;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; EQ 5D; HEALTH STATUS; HEALTH STATUS INDICATOR; HUMAN; META ANALYSIS; MICTURITION; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OAB 5D; OVERACTIVE BLADDER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED KINGDOM; URINARY FREQUENCY; URINE INCONTINENCE;

AGED; AUSTRALIA; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NORTH AMERICA; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; URINARY BLADDER, OVERACTIVE;

EID: 84887789358     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-200     Document Type: Article

References (22)

1. Abrams P, Artibani W, Cardozo L, Dmochowski R, Van Kerrebroeck P, Sand P,. International Continence Society Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009, 28(4):287. 10.1002/nau.20737, 19350662, International Continence Society.
2. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000, 6(Suppl 11):S574-S579.
3. Irwin DE, Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50(6):1306-1314. discussion 1314-5, 10.1016/j.eururo.2006.09.019, 17049716.
4. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal 2008, ISBN: 1-84629-741-9, National Institute for Health and Clinical Excellence.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine 1996, New York: Oxford University Press.
6. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997, 50(Suppl 6A):100-107. discussion 108-10.
7. Johannesson M, O'Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997, 80(4):557-562. 10.1046/j.1464-410X.1997.00420.x, 9352692.
8. Yang Y, Brazier J, Tsuchiya A, Coyne K. Estimating a preference-based single index from the overactive bladder questionnaire. Value Health 2009, 12(1):159-166. 10.1111/j.1524-4733.2008.00413.x, 18647258.
9. Stolk EA, Busschbach JJ. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res 2003, 12(4):363-371. 10.1023/A:1023453405252, 12797709.
10. Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes 2006, 4:89. 10.1186/1477-7525-4-89, 1675990, 17125512.
11. McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge pulmonary hypertension outcome review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008, 6:65. 10.1186/1477-7525-6-65, 2546377, 18718016.
12. Young T, Yang Y, Brazier JE, Tsuchiya A, Coyne K. The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. Qual Life Res 2009, 18(2):253-265. 10.1007/s11136-008-9428-0, 19082759.
13. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002, 11(6):563-574. 10.1023/A:1016370925601, 12206577.
14. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005, 24(3):215-225. 10.1002/nau.20110, 15747340.
15. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005, 14(3):849-855. 10.1007/s11136-004-0706-1, 16022077.
16. Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013, 63(2):283-295. 10.1016/j.eururo.2012.10.016, 23182126.
17. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013, 189(4):1388-1395. 10.1016/j.juro.2012.10.017, 23079373.
18. Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stölzel M, Martin N, Gunther A, Van Kerrebroeck P. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β(3)-adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013, 82(2):313-320. 10.1016/j.urology.2013.02.077, 23769122.
19. Dolan P, Jones-Lee M. The time trade-off: a note on the effect of lifetime reallocation of consumption and discounting. J Health Econ 1997, 16(6):731-739. 10.1016/S0167-6296(96)00514-0, 10176781.
20. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D 1999, York Centre for Health Economics, Discussion Paper 172. http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf.
21. Fryback DG, Dunham NC, Palta M, Hanmer J, Buechner J, Cherepanov D, Herrington SA, Hays RD, Kaplan RM, Ganiats TG, Feeny D, Kind P. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007, 45(12):1162-1170. 10.1097/MLR.0b013e31814848f1, 2647803, 18007166.
22. Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998, 17(6):599-611. 10.1002/(SICI)1520-6777(1998)17:6<599::AID-NAU4>3.0.CO;2-J, 9829424.